Biological Treatment for Liver Tumor and New Potential Biomarkers
The search for effective and efficacious therapy for liver tumor was started many years ago and is still ongoing. Despite all of the surgical advances, much work needs to be done to improve understanding of the biology of the tumor and its treatment. The rules of hepatic surgery are changing because of two recent major trends: (1) technical simplification, and (2) the endeavor to treat an increasing number of patients. T lymphocytes are potent cellular effectors of the immune system and possess a memory that responds to rechallenge by the same antigen. Being more specific and less toxic than chemotherapy, tumor infusion could be an ideal adjuvant therapy for patients with primary and secondary liver malignancies. Moreover, tumor cell vaccines have demonstrated efficacy in terms of minimal residual disease and are being investigated, but the requirement for an adequate supple of autologos tumor may limit the general applicability of these approaches. Various studies have demonstrated the aberrant expression of germ-cell proteins called cancer-testis (CT) antigens in liver neoplastic cells. Their selective normal-tissue expression makes them ideal antigens for immune targeting of malignant disease. Specific expression of CT antigens also suggests their application as tumor markers to detect circulating hepatocellular carcinoma (HCC) cells, as an adjuvant diagnostic tool, and as indicators for recurrence and prognosis. Biological therapy is now generating more clinical trials. More studies need to be performed and further experiments need to be done, although currently this seems a valid pathway for the treatment of liver cancer. Cytoreduction treatment of liver tumor and the vaccine might be the future of the treatment of primary and secondary liver tumor.
KeywordsLiver Tumors Surgery CTL Cytoreduction Immunotherapy Biological therapy Cancer-testis antigens Biomarkers
The present study is supported by the Institutional Research Program of the Texas Tech University Health Sciences Center and Southwest Cancer Treatment and Research Center program.
- 2.Lav WY (1997) This history of liver surgery. J R Coll Surg Edinb 42:303–309Google Scholar
- 4.Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A (2004) Surgical resection versus percutaneous RFA in the treatment of hepatocellular carcinoma in cirrhotic liver. Ann Surg 2:120–127Google Scholar
- 5.Carr BI, Selby R, Madariaga J, Iwatsuki S, Starzl TE (1993) Prolonged survival after liver transplantation and cancer chemotherapy for advanced-stage hepatocellular carcinoma. Trans Proc 25:1124–1125Google Scholar
- 6.Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT (1998) NIH conference on hepatocellular carcinoma. Ann Intern Med 108:390–401Google Scholar
- 13.Chiriva-Internai M, Grizzi F, Cobos E, Jumper C, Hermonat PL, Frezza EE (2005) Immunological treatment of liver tumours. World J Gastroenterol 11:6571–6576Google Scholar
- 15.Rossi S, Formari F, Paties C, Buscarini L (1990) Thermal lesions induced by 480-KHz localized current field in guinea pigs and in pig livers. Tumouri 76:54–57Google Scholar
- 17.Ellis LM, Chase J, Patt Y, Curley SA (1998) Hepatic arterial chemotherapy for colorectal cancer liver metastasis. In: Curley SA (ed) Liver Cancer. Springer Verlag Publishers, New York, pp 150–172Google Scholar
- 19.Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129PubMedCrossRefGoogle Scholar
- 20.Bouwens L, Wise E (1989) Hepatic pit cells have natural cytotoxic (NC) activity against solid tumour derived target cells. In: Wisse E, Knook DL, Decker K (eds) The Netherlands cells of the hepatic sinusoid. Kupffer Cell Foundation, Rijswijk, pp 215–220Google Scholar
- 34.Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ (1996) Phase I/II study of iodine-125-labeled monoclonal antibody A33 in patients with advanced colon Cancer. J Clin Oncol 14:1573–1562Google Scholar